IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

INTERPACE BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$5.00−0.15 (-2.91%)

Close on Oct 19, 2026

Market cap: $138.57M
P/E (TTM): 5.6
Dividend yield: –

INTERPACE BIOSCIENCES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2007 2007-12-31
Revenue	39	47	40	32	8.20	32	24	22	16	13	9.43	1.47	147	127	157	135	–
Cost of Revenue	15	17	15	14	14	22	16	10	7.36	6.64	6.91	1.27	123	100	125	108	–
Gross Profit	24	30	25	18	19	11	8.33	12	8.54	6.44	2.52	0.21	24	27	32	27	–
Research & Development	0.64	0.68	0.64	0.70	1.49	2.80	2.81	2.12	1.46	1.65	2.29	0.26	–	–	–	–	–
Selling, General & Admin	19	21	20	20	20	27	25	17	16	16	27	15	–	–	–	–	–
Selling & Marketing	9.92	12	10	9.13	9.18	9.25	11	8.42	6.57	5.46	10	0.60	–	–	–	–	–
General & Administrative	9.48	9.49	9.36	11	11	18	14	8.68	9.15	11	17	14	–	–	–	–	–
Operating Expenses	20	22	21	22	25	37	35	24	15	13	43	18	25	52	37	33	–
Operating Income	4.08	8.11	3.96	-3.62	-6.34	-26	-26	-13	-6.29	-6.44	-40	-18	-1.44	-25	-4.70	-6.90	–
Interest Expense	–	–	–	–	–	0.55	0.44	0.33	0.43	2.14	3.71	0.60	0	–	–	–	–
Income from Equity Investments	–	8.10	2.80	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	–	–	-0.67	-1.21	-0.37	0.47	0.20	0.26	-2.13	0.01	-0.09	-0.07	-0.06	-0.03	-0.01	0.12	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	0	0.71	0.39	2.00	1.00
Asset Impairment Charges	0.20	–	–	8.43	–	0.04	–	–	–	12	0.64	2.09	0	24	0	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	-0.01	–	–	–	–	1.33	21	1.20	–	–	–	–	–
Pretax Income	3.77	6.95	2.28	-5.84	-7.74	-26	-27	-13	-13	-8.57	-44	-18	-1.50	-25	-4.72	-6.78	–
Income Tax Expense	-21	0.00	0.02	0.03	-0.71	0.05	-0.03	0.02	-0.40	-0.16	-13	-5.03	0.18	0.21	-0.94	0.39	–
Income from Continuing Operations	4.10	6.95	2.26	-5.87	-7.04	-26	-27	-13	-13	-8.41	-31	-13	-1.68	-25	-3.78	-7.18	–
Income from Discontinued Operations	-0.41	-0.24	-0.31	-16	-7.91	-0.25	-0.09	0.02	0.52	0.08	20	-2.61	-2.89	-0.06	-8.14	0.36	–
Net Income	25	6.70	1.95	-22	-15	-26	-27	-13	13	-22	-14	-17	-4.57	-26	-12	-6.81	–
Preferred Dividends	–	0.46	–	–	–	–	0.43	–	–	–	–	–	–	–	–	–	–
Net Income to Common	25	6.24	1.95	–	-15	-29	-27	-13	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	5.55	1.42	0.45	-5.18	-3.61	-7.32	-7.25	-4.52	-7.96	-120.90	-87.95	-112.53	-31.00	-175.00	-83.00	-48.00	–
EPS (Diluted)(per share)	0.89	0.40	0.45	-5.18	-3.61	-7.32	-7.25	-4.52	-7.96	-120.90	-87.95	-112.53	-31.00	-175.00	-83.00	-48.00	–
Shares Outstanding (Basic, Weighted)(shares)	4.42	4.39	4.32	4.24	4.14	4.03	3.75	2.82	1.58	0.18	0.15	0.15	0.15	0.15	0.14	0.14	–
Shares Outstanding (Diluted, Weighted)(shares)	28	16	4.36	4.24	4.14	4.03	3.75	2.82	1.58	0.18	0.15	0.15	0.15	0.15	0.14	0.14	–
EBITDA	4.51	8.41	4.98	-1.06	-0.96	-21	-22	-8.83	-2.60	-1.96	-35	-15	-0.01	-23	-1.66	-5.07	–
Net Interest Income	–	–	-0.11	-0.16	-0.50	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 63.7%
Operating margin: 11.5%
Net margin: 67.6%
Return on equity, FY2025: 244.0%

Financial strength

Current ratio: 2.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 54.3%

Valuation

P/E ratio: 5.6
Price to sales: 3.83
Price to book: 5.96
Dividend yield: –